Yeah, I would say that randomized trials will be needed. The design of those should be guided by what is now quite a bit of accumulating data. There are multiple ongoing randomized trials in the current metastatic setting with pembrolizumab, with some of the other HPV-specific therapeutic vaccine strategies. But I think that we need to continue testing these in the neoadjuvant setting, both as a strategy to improve outcomes in patients with higher-risk HPV-positive head-and-neck cancer, as well as a strategy to try to de-escalate the toxicity associated with radiation...
Yeah, I would say that randomized trials will be needed. The design of those should be guided by what is now quite a bit of accumulating data. There are multiple ongoing randomized trials in the current metastatic setting with pembrolizumab, with some of the other HPV-specific therapeutic vaccine strategies. But I think that we need to continue testing these in the neoadjuvant setting, both as a strategy to improve outcomes in patients with higher-risk HPV-positive head-and-neck cancer, as well as a strategy to try to de-escalate the toxicity associated with radiation.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.